Lingating, Esterlita .
HRN: 06-81-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/04/2024
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
05/04/2024
05/14/2024
IV
500mg
Q24
Infected Wound, Breast
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes